<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655692</url>
  </required_header>
  <id_info>
    <org_study_id>SPLE-003-14W</org_study_id>
    <nct_id>NCT02655692</nct_id>
  </id_info>
  <brief_title>CAP-Ketamine for Antidepressant Resistant PTSD</brief_title>
  <official_title>CAP-Ketamine for Antidepressant Resistant PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as
      compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an
      active duty military and Veteran population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this 2-site clinical trial, intended to evaluate the safety and efficacy of repeated doses
      of ketamine for treatment resistant PTSD, Veterans and active duty military personnel who
      meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized
      to one of three treatment arms (placebo, low dose ketamine, high dose ketamine). Participants
      receive the study drug via intravenous infusion twice per week for 4-weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD Checklist to measure change in PTSD symptoms from baseline to post-treatment (4 weeks)</measure>
    <time_frame>24-hours post-infusions; weekly for 4 weeks following last infusion</time_frame>
    <description>The PTSD Checklist (PCL) is a brief measure of the symptoms of Posttraumatic Stress Disorder. Item and total scores will be recorded and aggregated from all study participants.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>PTSD</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Ketamine (.20 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Ketamine (.50 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>FDA approved anesthetic medication with rapid acting antidepressant effects.</description>
    <arm_group_label>Low Dose Ketamine</arm_group_label>
    <arm_group_label>High Dose Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is a saline placebo/non-active solution.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female Veterans or active duty military personnel between the ages of 18 and
             70 years

          -  diagnosis of PTSD

          -  history of trialing one or more antidepressant medications with little to no PTSD
             symptom improvement

          -  ability to provide written informed consent

        Exclusion Criteria:

          -  females who are currently pregnant or breastfeeding

          -  current risk for suicide

          -  history of severe head injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H. Krystal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynnette Averill</last_name>
    <email>Lynnette.Averill@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynnette Averill</last_name>
      <email>Lynnette.Averill@va.gov</email>
    </contact>
    <investigator>
      <last_name>John H. Krystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bill Murff, BS</last_name>
      <phone>210-539-9422</phone>
      <email>murff@uthscsa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Veteran</keyword>
  <keyword>Military</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

